TCRR — TCR2 Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $58.11m
- -$52.20m
- 35
- 47
- 64
- 47
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 26.5 | 51.4 | 68.7 | 99.7 | 153 |
Operating Profit | -26.5 | -51.4 | -68.7 | -99.7 | -153 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -24.3 | -47.5 | -67 | -99.5 | -152 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.3 | -47.6 | -67.1 | -99.8 | -152 |
Net Income Before Extraordinary Items | |||||
Net Income | -24.3 | -47.6 | -67.1 | -99.8 | -152 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -61.5 | -97.5 | -67.1 | -99.8 | -152 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.57 | -4.62 | -2.4 | -2.57 | -3.41 |